Biologics by McKesson

08/06/2026

August is ☀️ Summer Sun Safety Month! ☀️

This is a great time to get out and enjoy the good weather. But it's also important to protect your skin. Cancers like melanoma, one of the most fatal skin cancers, can be caused by sun exposure.

Luckily, there are a lot of things you can do to reduce your risk:

☀️ Protect yourself by wearing hats and sunglasses to protect your skin and eyes
☀️ Apply sunscreen regularly (SPF 30 or higher is best)
☀️ Avoid the sun between the hours of 10:00 AM and 4:00 PM, when UV rays are the strongest
☀️ Get an annual skin check with your doctor

Biologics is proud to work with providers who are helping patients stay healthy this season!

08/03/2026

We're proud to share that Biologics has been reaccredited by URAC as a Specialty Pharmacy. We have also been designated as a Rare Disease Pharmacy Center of Excellence.

This reflects the hard work and commitment our team shows every day. Thank you for everything you do to put patients first!

In this video, Gregory Wolfe, VP and COO, talks about what this accomplishment means for patients and for our team.

Learn more about our accreditations: https://lnkd.in/eNPXv-ZX

07/31/2026

World Lung Cancer Day is coming up tomorrow (August 1st). It's a reminder that raising awareness can have a big impact on research, earlier diagnosis, and treatments that bring new hope to patients and their families.

With an estimated 229,410 new cases of lung cancer projected in the U.S. over 2026, it's more important than ever to improve research and care.

Biologics supports a broad range of lung cancer therapies, helping care teams move from referral to treatment with less friction and more support.

We stand with patients, families, and providers to support those affected by lung cancer—and to help build a healthier future.

Learn more: https://biologics.mckesson.com/providers/specialty-drugs-list/

07/29/2026

Patient journeys can be complex, often leading to delays in care.

To reach those patients, you need to have hub services that are flexible enough to meet them where they are. And you need a system that will allow you to continue to scale.

Biologics' PharmacyElite™ hub solution is designed to be one of a kind. It allows us to work together with our partners to bring your therapies to market—and make sure patients have access to them.

Learn how we help get therapies to the patients who need them: https://biologics.mckesson.com/hub-services/

07/28/2026

Living with a rare disease can be tough. There's the illness itself, of course. But it can also be hard to find the support you need.

This is where groups like the Friedreich's Ataxia Research Alliance (FARA) come in. FARA offers comfort to those living with Friedreich’s ataxia (FA). The group's goal is to fund research that can slow, stop, and cure this disease. Their efforts ensure that no one with FA has to feel alone.

Biologics is proud to continue our support of FARA. We were a silver sponsor of this year's Cure FA Soirée, an event that raised $620,000 for FA research. Daniel Weaver, Clinical Science Liaison; Christian Hawkins, Director, Client Relationship, McKesson; Parker DeRosier, Senior Sales Executive; and Azraa Holloway, Regional Practice Liaison, were part of the celebration.

We're honored to help spread the word about FARA's work and what it means for those living with FA.

07/27/2026

It can be heartbreaking to find out that your cancer treatment has stopped being effective. It also raises questions about what options are still on the table.

With estrogen receptor (ER)-positive breast cancer, treatments can become less effective over time. ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated breast cancer involves mutations that can make treatment more difficult. That's why new, targeted therapies are so important.

Today, we're proud to share that Biologics has been chosen by Rigel Pharmaceuticals as the Hub and a limited distribution specialty pharmacy for VEPPANU™ (vepdegestrant). This drug treats adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

“VEPPANU™ represents an important advancement for patients with ESR1-mutated breast cancer," says Ela Lourido, vice president and general manager, Biologics by McKesson. "We are proud to expand our relationship with Rigel as the exclusive Hub and a specialty pharmacy provider for this therapy."

New treatments can bring hope to cancer patients and their families. We're honored to help patients get the care and support they need throughout their treatment journey.

Learn more: https://biologics.mckesson.com/veppanu-vepdegestrant-fda-approved-for-treatment-of-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer-available-at-biologics-by-mckesson

07/24/2026

At Biologics, we believe that patient-centered care should focus on more than just the clinical. Our work is built on trust, compassion, and taking the time to truly listen to every patient.

That's why we're proud to share that we have received a score of 97.6 on the Medallia + Arnold P. Gold Foundation Humanism Trust Tool. This tool measures the most important part of healthcare: human connection.

Every day, our team shows up for patients who are navigating the world of complex therapies. It's vital for these patients to know they have a trusted partner in their corner. Plus, when we bring empathy and respect to the table, we can improve outcomes.

We’re proud of this milestone score. And we're even more committed to continuing to raise the bar.

Learn more: https://biologics.mckesson.com/

07/20/2026

🎗️🦴 Did you know? July is Sarcoma & Bone Cancer Awareness Month. 🎗️🦴

Sarcomas are a rare group of cancers that form in the bones or soft tissues of the body. This includes muscles, fat, nerves, and blood vessels. Sarcoma types and incidence can vary by age group. For example, about a quarter of bone and joint cancer cases are diagnosed in people under age 20. But soft tissue cancers tend to mostly affect those over age 55.

🔍 Key Facts:

— It's not always easy to tell a sarcoma apart from other kinds of cancer when it shows up in an organ.

— Sarcomas make up 1% of all adult cancers and 15-20% of all childhood cancers.

— Recent research is looking at how to develop targeted treatments with tumor profiling, nanomedicine, and T-cell therapy.

Every day, care teams are working hard to support these patients and find ways to improve outcomes. At Biologics, we're proud to stand with those who are living with these cancers.

07/16/2026

🧠 Today, July 16th, is Glioblastoma Awareness Day. 🧠

Glioblastoma (GBM) is an aggressive, cancerous brain tumor known for its rapid progression and resistance to treatment. As one of the deadliest types of cancer, it can be a challenging and complex diagnosis.

However, there is hope.

Recent progress has led to exciting new brain tumor drug approvals, with more promising options on the horizon. Now is the time to keep the momentum going and offer support to those living with this cancer.

📊 Did You Know?

— GBM can affect anyone at any age, but it tends to be more common in older people, often around age 64.

— Even with treatment, median survival is typically just over a year.

— This year, there will likely be about 14,000 new cases in the U.S.

At Biologics, we're excited about ongoing research and advancements in treatment options. We're proud to support these patients on their treatment journeys.

07/15/2026

Proud to see our own Daniel Weaver helping to get the word out about TGCT! TGCT Support's Day of Learning event is an important opportunity to learn more about TGCT and brainstorm how we can better support patients with this rare disease. Biologics is proud to walk with these patients on their journeys and make sure they know they're not alone.

Learn more about TGCT Support and their work: https://www.tgctsupport.org

And find out more about the Day of Learning here: https://www.linkedin.com/posts/daniel-weaver-io_biologicsbymckesson-tgct-ugcPost-7482529255948546050-4JxI/

TGCT Support is a nonprofit patient advocacy program created to bring resources to the community of patients with TGCT/PVNS.